cyclosporin A microemulsion / Generic mfg. - LARVOL DELTA

Monovalent mannose-glycoconjugates of sulforaphane reprogram human dendritic cells via NFATc1 to induce immune tolerance under inflammatory conditions. (PubMed, Br J Pharmacol) - "Our findings identify NFATc1 as a key transcriptional switch in moDCs tolerogenic programming and highlight the carbohydrate-dependent specificity of SFN conjugates. SFNMan represents a novel carbohydrate-engineered immunomodulator capable of driving immune tolerance through NFATc1 activation. These results provide a mechanistic framework for the development of precision therapies targeting inflammatory and autoimmune diseases."

Journal • Immunology • Inflammation • CD86 • IL10 • NFATC1 • PD-L1 • SOCS1

Enhanced outcomes for pediatric patients with de novo chronic myeloid leukemia in blast Phase through early allogeneic stem cell transplantation and tyrosine kinase inhibitor (ASH 2025) - "Specifically, dasatinib was administered to four patients, while olverembatinib for three patients...Prophylaxis for graft-versus-host disease (GVHD) routinely included cyclosporine A and mycophenolate mofetil, with or without methotrexate... Prompt HSCT for de novo CML-BP, combined with early TKI maintenance post-transplantation, appears to contribute to effective disease management. Additionally, unrelated cord blood donors seem to provide a viable source for transplantation. Furthermore, olverembatinib has demonstrated favorable safety and efficacy profiles both pre- and post-transplantation."

Clinical • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Myeloid Leukemia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Pediatrics • Transplantation • ABL1

Hetrombopag for enhancing platelet engraftment after haploidentical allogeneic hematopoietic stem cell transplantation in patients with severe thalassemia: An observational study (ASH 2025) - P | "Graft-versus-host disease prophylaxis included cyclophosphamide at a total dose of 100 mg/kg (divided into two doses on day +3 and +4), methotrexate at 10 mg/m² (administered on days +1, +2, +5, and +6), and cyclosporine A at 4 mg/kg/day starting from day +6. A significant difference in transfusion volume between groups may have introduced bias in post-transplant outcome analysis. These findings suggest that relying solely on platelet engraftment time as a measure of engraftment efficacy may be inadequate and potentially limiting."

Clinical • Observational data • Beta-Thalassemia • Bone Marrow Transplantation • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Liver Failure • Musculoskeletal Pain • Nephrology • Transplantation

Real-world experience with hematopoietic stem cell transplantation in acute leukemias: Clinical landscape and impact of early cyclosporine a exposure on post-transplant complications and outcomes (ASH 2025) - "Relapse was associated with ≥3 prior treatment lines and lack of maintenance therapy in B-ALL, and with MRD positivity post-transplant in AML. These findings underscore the importance of optimizing immunosuppression, implementing therapeutic drug monitoring, and developing robust post-transplant strategies."

Clinical • Post-transplantation • Real-world • Real-world evidence • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Transplantation

Transplant outcomes for children and adolescents with severe aplastic anemia comparing matched sibling donor and haploidentical transplant approaches. (ASH 2025) - "Introduction Recent studies comparing matched sibling donor (MSD) and haploidentical donor with post-transplant cyclophosphamide (haplo-PTCy) hematopoietic stem cell transplantation (HSCT) for children and adolescents with severe aplastic anemia (SAA) show promising results...GVHD prophylaxis included cyclosporine A (3–5 mg/kg) and mini-methotrexate...The conditioning regimen included ATG 4.5 mg/kg, fludarabine 150 mg/m², and total body irradiation 400 cGy. GVHD prophylaxis consisted of Cy 50 mg/kg on +3 and +4, followed by tacrolimus 0.06 mg/kg and mycophenolate mofetil 30 mg/kg starting on +5...Discussion and Conclusions Health-related quality of life outcomes is comparable between the two approaches, with no significative differences in overall survival between both transplant models. These results suggest that haplo-HSCT with PT-Cy is a viable alternative when an MSD is unavailable and may open the possibility of further research studies in which this transplant..."

Clinical • Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Respiratory Diseases • Transplantation

Orelabrutinib in the treatment of pure red cell aplasia after allogeneic hematopoietic stem cell transplantation (ASH 2025) - "Reported therapeutic strategies for post-transplant PRCA include Rituximab, Bortezomib, Cyclosporine A, Glucocorticoid, Cyclophosphamide, Daratumumab, and erythropoietin. Orelabrutinib has demonstrated both safety and efficacy in eliminating autoantibodies targeting erythroid precursor cells. Thus, it represents a viable therapeutic option for refractory post-transplant PRCA following ABO-incompatible allo-HSCT."

Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Transplantation

Safety and feasibility of outpatient myeloablative total marrow and lymphoid Irradiation–based allogeneic transplantation in adults with high-risk acute lymphoblastic leukemia (ASH 2025) - "The conditioning regimen wascyclophosphamide (Cy) 350 mg/m² and fludarabine25 mg/m² (day -6 to -4) followed by TMLI; 12 Gy in 6fractions of 2 Gy every 12 hours (day -3 to -1) delivered using a tomotherapy system...Graft-versus-host disease (GVHD) prophylaxisconsisted in tacrolimus or cyclosporin A started on day 0 followed by Cy 30 mg/kg for matched relatedand 40 mg/kg for haploidentical HSCT on day +3 and +4, and mycophenolate mofetil starting on day +5-30. Filgrastim (300 mcg/day) was started on day +5 until stable engraftment...Themedian prior therapy lines were 3 (range, 2-4), 50% blinatumomab-exposed...One-yearOS, RFS, CIR and NRM rates were 81.3%, 80%, 24% and 7.1% respectively. Conclusion TMLI-based conditioning in adolescents and young adults with ALL was feasible and safe, allowing for afull-outpatient conduct in 57% of patients, supporting further studies assessing its efficacy and the safetyof larger doses."

Clinical • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Anorexia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Gastroenterology • Gastroesophageal Reflux Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Mucositis • Neutropenia • Stomatitis • Transplantation

FK506 improves B cell reconstitution after allo-HSCT compared to csa: A real-world study (ASH 2025) - "Calcineurin inhibitors(CNIs), including Cyclosporine A (CsA) and Tacrolimus (FK506), are widely used immunosuppressiveagents in allo-HSCT...Prophylaxis regimens included either tacrolimus (FK506, administered at 0.05mg/kg twice daily intravenously, adjusted to maintain a trough level of 5–15 ng/mL) or cyclosporine (CsA,administered at 3.0 mg/kg/day intravenously from day −1, adjusted to maintain a trough level of 200–300ng/mL)...Additionally, we observed a potential association between bonemarrow B-cell recovery around day +100 and viral infections. Through mediation analysis, we furtherexplored the relationship between FK506, B-cell reconstitution, and viral infection, revealing that B cellsplayed a mediating role in the impact of FK506 on post-transplant viral infection."

Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease

MO-TRANS update: A randomized, double-blind, placebo-controlled, multi-center phase III study of mocravimod (MOC) as maintenance treatment in AML patients undergoing allogeneic hematopoietic cell transplantation (ASH 2025) - P1, P3 | "Use of ATG,alemtuzumab, cyclosporine A (CsA), and abatacept is excluded; other GvHD prophylaxis agents such aspost-transplant cyclophosphamide (PTCy) are permitted. There is an unmet medical need to maintain CR after allo-HCT, especially in AMLpatients with high risk factors or previous relapse. The MO-TRANS study aims to validate the therapeuticpotential of MOC in reducing relapse and GvHD in patients allografted for AML."

Clinical • P3 data • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Chronic Graft versus Host Disease • Diabetes • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Macular Edema • Metabolic Disorders • Ocular Inflammation • Ophthalmology • Transplantation • Uveitis

Real-world outcomes of eltrombopag-containing regimens as frontline treatment for aplastic anemia: A multi-center retrospective study (ASH 2025) - "Treatment regimens included EPAG(N=8), EPAG+cyclosporin A (CsA) (N=58) and EPAG+CsA+antithymocyte globulin (ATG) (N=52).For MAA patients, most were treated with EPAG+CsA (N=14). Early treatment initiation might benefitAA patients. These findings highlight the need for prospective trials to optimise EPAG-based strategies.Finally, prospective comparison with frontline allogeneic HSCT is also warranted."

Real-world • Real-world evidence • Retrospective data • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases

The CSMD1 gene is involved in hematopoietic stem cell HSC pruning in patients with acquired immune-mediated aplastic anemia (ASH 2025) - P3 | "Here we present a deep analysis of CSMD1 mutations in IAA patientsenrolled in the RACE trial, looking for the frequency of mutations, its association with clinical variablesand other somatic mutations, the dynamics of the mutated clones across the 2-year study period and ain silico structural analysis predicting functional consequences.MethodsThe RACE trial enrolled 197 IAA patients randomized to receive standard IST (anti-thymocyte globulin[ATG] and cyclosporine A) with or without eltrombopag. Although CSMD1is a known tumor suppressor gene, in the context of IAA clones carrying specific CSMD1 mutation mighthave a transient survival advantage in the context of hematopoietic toxicity during ATG treatment. Thus,CSMD1-mutated HSC/HCP seem to be an example of pruning selection, where some intrinsic advantagetransiently emerging in specific micro-environmental setting may eventually become evident at the timeof hematological recovery."

Clinical • Anemia • Aplastic Anemia • CSMD1 • PHF6 • PPM1D • PTPN11 • RAD21 • STAG2

Novel insights from the largest cohort to date: Elucidating risk factors, clinical outcomes, and prognostic predictors in autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation (ASH 2025) - "Prednisolonecombined with Rituximab, as the first-line treatment regimen, has been found to increase the likelihoodof patients with post-allo-HSCT AIHA achieving a CR/R (log rank p = 0.003); however, this treatmentprotocol did not improve overall survival. Furthermore, other currently recommended therapeuticinterventions, including corticosteroids alone, plasma exchange, cyclosporine A, and mycophenolatemofetil have demonstrated no significant positive effects on treatment response or long-term survival.Additionally, no obvious adverse reactions were observed.According to the prognostic analysis, the mononuclear cell count at allo-HSCT (HR 1.720, p = 0.011) wasfound to be an independent predictor of AIHA relapse...Further analyses identified risk factors and clinical outcomes and, forthe first time, elucidated prognostic predictors of post-allo-HSCT AIHA. These findings innovativelyhighlight key prognostic markers, guiding risk stratification and the management of AIHA..."

Clinical • Clinical data • Acute Graft versus Host Disease • Acute Kidney Injury • Anemia • Autoimmune Hemolytic Anemia • Bone Marrow Transplantation • Complement-mediated Rare Disorders • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Liver Failure • Nephrology • Renal Disease • Transplantation • CRP

Adding eltrombopag to immunosuppressive treatment with cyclosporine as front-line therapy for moderate aplastic anemia improves trilineage hematologic response: One-year analysis of the randomised, placebo-controlled, double-blind Phase III trial eltrombopag for moderate aplastic anemia (EMAA Trial) (ASH 2025) - P2/3 | "Introduction:Eltrombopag (EPAG) combined with horse antithymocyte globulin and cyclosporine A (CSA) when givenas first-line treatment of patients (pts) with severe aplastic anemia (SAA) improves rate, rapidity, andstrength of hematologic response. Adding EPAG to CSA treatment for first-line treatment of MAA significantly improves trilineagehematologic response at wk 24. Addition of EPAG in pts without CR after 24 wks of single-agent CSAtreatment also improves the trilineage hematologic response rate. The cumulative incidence of trilineageresponse was significantly better in pts randomized into the EPAG arm."

Clinical • P3 data • Anemia • Aplastic Anemia • Cardiovascular • Hematological Disorders • Pulmonary Embolism • Respiratory Diseases

Efficacy of daratumumab in treatment of relapsed and/or refractory warm autoimmune hemolytic anemia in children (ASH 2025) - "Treatment options for steroiddependent, refractory/relapsed (r/r) wAIHA include rituximab, mycophenolate mofetil (MMF), and otherimmunosuppressants with splenectomy reserved for select cases...She was treated with steroids, rituximab, cyclosporine A (CSA), MMF, bortezomib,abatacept, sirolimus, and fostamatinib with multiple relpases...He was started on MMF anddaratumumab with remarkable recovery of hemolysis within 1 week; remains transfusion independent at1 month follow-up.Patient 4: A Caucasian girl diagnosed at 5 months of age with immunoglobulin G & complementmediated wAIHA initially responsive to prednisone and rituximab; she developed nephrotic syndromeand lupus nephritis by 1 year of age, complicated by renal failure. Multiple relapses of wAIHA weretreated with rituximab, cyclophosphamide, CSA, MMF, sirolimus, eculizumab, raviluzimab, andpegcetacoplan... In our experience daratumumab showed remarkable efficacy in treating r/r wAIHA inchildren. Responses were..."

Clinical • Anemia • Autoimmune Hemolytic Anemia • Glomerulonephritis • Hematological Disorders • Hematological Malignancies • Immune Thrombocytopenic Purpura • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Multiple Myeloma • Nephrology • Renal Disease • Thrombocytopenia • Thrombocytopenic Purpura

Comprehensive multiproteomic analysis reveals an inflammatory phenotype in immune aplastic anemia characterized by broad activation of antigen presenting cells and t helper/cytotoxic 1.17 immune responses (ASH 2025) - "Most compelling evidence that HSPC destruction isimmune-mediated is that two-thirds of severe AA patients demonstrate hematologic improvement inresponse to immunosuppressive therapy consisting of anti-thymocyte globulin and cyclosporin A.Interferon γ (IFNγ) and tumor necrosis factor α (TNFα) have both been implicated as critical effectormolecules involved in the destruction of bone marrow HSPCs in AA... In this study, we confirmed that AA is characterized by significant increases in severalhematopoietic growth factors in the periphery, which may reflect compensatory mechanisms thatcounterbalance the lack of blood cell production in the bone marrow. Furthermore, we demonstratedthat AA is an autoimmune disease characterized by an inflammatory phenotype biased towards aTh/c1.17 immune response and increased circulating Th1 and Th17 cytokines (e.g. IFNγ and IL17A/F).Finally, we showed that multiple APCs may participate in antigen presentation in AA, as both B cells..."

Omic analysis • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Immunology • Neutropenia • Thrombocytopenia • CCL20 • CCR6 • CCR7 • CD4 • CD8 • CXCR3 • FLT3 • FLT3LG • HLA-DRB1 • IFNG • IL15 • IL17A • IL2 • IL2RA • TNFA

Incidence and characteristics of myeloid neoplasms in patients with multiple myeloma treated with novel myeloma-directed therapies (ASH 2025) - "Twenty-three patients had undergone ASCT, 9 of whom received a second ASCT.Maintenance therapy was administered in 20 patients: 17 received lenalidomide (median 17 cycles; range4–115), and 3 received thalidomide (median 13 cycles; range 11–48)...Among AML cases, 6 received intensive induction (FLAI+venetoclax in 4, CPX-351 in2); 2 received azacitidine+venetoclax...GVHD prophylaxis included methotrexate,cyclosporine A, and rATG for matched donors, and post-transplant cyclophosphamide, mycophenolatemofetil, and tacrolimus for haploidentical transplants...Early identification and molecular profiling are essential for diagnosis and risk stratification.Allo-SCT remains the only potentially curative approach. These findings underscore the need for long-term monitoring and individualized management strategies in MM survivors."

Clinical • IO biomarker • Acute Myelogenous Leukemia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Multiple Myeloma • Myelodysplastic Syndrome • CSF3R • DNMT3A • KRAS • NRAS • RUNX1 • TP53

Preliminary efficacy and safety of golidocitinib in relapsed/refractory T cell and NK cell large granular lymphocyte leukemia (ASH 2025) - P2 | "Immunosuppressive therapy remains the standard first linetreatment, including methotrexate, cyclosporine A, and cyclophosphamide...Sixpatients had failed three or more prior lines including PI3Kδ inhibitor linperlisib and JAK1/2 inhibitorruxolitinib...Golidocitinib monotherapy demonstrates compelling clinical activity, including 100% response amongSTAT3 wild type evaluable patients, and a favorable safety profile in heavily pretreated r/r T-LGLLpatients. These results support its further development in this population with unmet medical needs."

Clinical • Autoimmune Hemolytic Anemia • Cutaneous T-cell Lymphoma • Gastrointestinal Disorder • Hematological Malignancies • Herpes Zoster • Immunology • Indolent Lymphoma • Leukemia • Lymphoma • Natural Killer/T-cell Lymphoma • Neutropenia • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • Varicella Zoster • PIK3CD • STAT3

Young (35 years) matched sibling donors for allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT (ASH 2025) - "Bone marrow was the stem cell source in 19% of the yHaplo vs.5% of the oMSD grafts (p<0.001), following myeloablative conditioning (MAC) in 56.4% vs. 51% (p=0.35).PTCy was most frequently combined with cyclosporine A /mycophenolate mofetil-basedimmunosuppression as graft-versus-host disease (GvHD) prophylaxis, 62.8% vs.58 %, respectively.Thiotepa/busulfan was the most frequent conditioning in yHaplo pts, while it was busulfan/fludarabine inthe oMSD group. In this registry-based retrospective analysis of HSCT with PTCy for sAML in first completeremission, comparing yHaplo to oMSD, we observed similar transplantation outcomes, but a higherincidence of NRM and slower neutrophil engraftment, while a lower incidence of ext cGvHD was observedin the yHaplo compared to the oMSD grafts."

Clinical • Post-transplantation • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • Transplantation

Novel small molecule inhibitors of mitochondrial permeability transition pore (mPTP) block platelet procoagulant activity (ASH 2025) - "However, traditional therapeutic mPTP inhibitors, such as cyclosporine A, which targetcyclophilin D (CypD), exhibit off-target effects and cytotoxicity, limiting their clinical application. Injury size was comparable between groups.Altogether, our findings support MC63 and TR002 as selective inhibitors of platelet mPTP, andprocoagulant platelet activity, effectively limiting thrombosis without impairing essential hemostaticfunctions. These data highlight pharmacologic mPTP inhibition as a promising approach to saferantithrombotic therapies."

Cardiovascular • Hematological Disorders • Thrombosis • ANXA5 • PPIF • SELP

Clinical outcomes following single unrelated cord blood transplantation with ATG conditioning regimen for the treatment of mucopolysaccharidosis (ASH 2025) - "Graft-versus-host disease (GVHD)prevention involved using cyclosporine A (CsA) or tacrolimus (FK506) combined with mycophenolatemofetil (MMF). 95.12% of the children (39/41) who underwent UCBT were successful. The engraftment rate and survival rate of patients with MPS who underwent single UCBT withATG-containing conditioning regimen were high. The levels of Treg cells of low-dose ATG group wereincreased in the early stage after transplantation, which not only did not increase the graft failure riskand GVHD incidence, but also reduced the rate of CMV reactivation. Therefore, it is recommended toconsider low-dose ATG in UCBT conditioning regimen to achieve a high engraftment rate and low risk ofinfection."

Clinical • Clinical data • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Transplantation • CD8

Conditioning with alkylating agents, cytarabine, cladribine, hypomethylating agents, and venetoclax (ARCHIVE) for upfront allogeneic stem cell transplantation in patients with active Acute Myeloid Leukemia or myelodysplastic syndrome with increased blasts-2 (ASH 2025) - "The patients were older than 18 years and had AML or MDS-IB2 with >5% blasts and/orextramedullary disease.ARCHIVE conditioning consisted of cytarabine 500 or 1000 mg/m2, cladribine 5 mg/m2 on days -8, -7, -6, -5, -4, venetoclax 600 mg/d and decitabine 20 mg/m2 / azacitidine 75 mg/m2 on days -8, -7, -6, -5, -4, -3, -2. The backbone alkylating agent was either busulfan (3.2 mg/kg on days -3 and/or -2) or melphalan (100mg/m2 on day -2 in patients with previous busulfan exposure), whereas thiotepa (5 or 10 mg/kg on day -3or -4) was added to busulfan or melphalan in individual cases...GVHD prophylaxis consisted of post-transplant cyclophosphamide 40 mg/kg ondays +3 and +4, cyclosporine A (from day -1 and continued individually with tapering from day +70, targetconcentration 200-400 mcg/l), and mycophenolate mofetil 3 g/d (days 0-30).We collected baseline patient characteristics, disease-related factors, CR + CRp rate at day +30 afteralloSCT, MRD negativity rate (by..."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Graft versus Host Disease • Hepatology • Immunology • Mucositis • Myelodysplastic Syndrome • Transplantation • BCR • FLT3

Deep immune signature of immune-mediated aplastic anemia patients shows distinct subsets of regulatory T cells associated with response to treatment: Results from the phase 3, randomized EBMT race clinical trial (ASH 2025) - "Introduction: Immune-mediated aplastic anaemia (AA) is bone marrow failure syndrome, where T-cellmediated destruction of hematopoietic stem and progenitor cells (HSPCs) results in pancytopenia.Overall, two third of patient respond to immune suppressive therapy (IST) with antithymocyte globulin(ATG) and cyclosporine A (CsA), adding eltrombopag (EPAG) further improves response, but the immunesignatures that predict outcome remain unclear. We studied at diagnosis 130 previously untreated severe/very-severe AA patients enrolled in arandomised phase-3 trial of hATG + CsA with (Arm B, n = 65) or without EPAG (Arm A, n = 65). In summary, AA is characterized by a broadly shared immune activation state marked byreduced innate immunity and expanded effector T-cell subsets. Within this framework, two regulatory T-cell subsets, naïve and memory Tregs, emerge as independent predictors of treatment response,regardless of age. After treatment they remained stable in CR and PR;..."

Clinical • IO biomarker • P3 data • Anemia • Aplastic Anemia • Hematological Disorders • CCR4 • CD27 • CD8 • HLA-DRB1 • ITGAE • PD-1

T cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT (ASH 2025) - "Bone marrow(BM) grafts (22.9% vs. 3.7%, p0.5 x 109/L at day 30 was 86.9% (95%CI 83.9% -89.4%) for HaploSCT and 91.8% (95%CI 84% - 95.9%) for MMUD, with neutrophil recovery significantlyfaster in the MMUD group (hazard ratio (HR)=1.43 (1.09-1.86), p=0.009)... In this large retrospective study comparing HaploSCT and MMUD HSCT with PTCy-basedGVHD prophylaxis in sAML at CR1, outcomes were comparable between the two groups, except for fasterneutrophil recovery with MMUD. Results appear improved compared to historical data, likely due toPTCy. In the absence of an HLA-matched donor, both HaploHSCT and MMUD are potential alternatives."

Clinical • Post-transplantation • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • Transplantation

Autoimmune Thrombocytopenia Treated by Low-Dose Splenic Irradiation Followed by Splenectomy in a Patient With Systemic Lupus Erythematosus. (PubMed, Clin Case Rep) - "Despite multiple therapies, including prednisolone, cyclophosphamide, cyclosporine A, danazol, rituximab, and high-dose IVIg, thrombocytopenia persisted. LDSI (15 Gy in 15 fractions over 5 weeks) was performed, leading to rapid platelet recovery and enabling safe splenectomy, resulting in long-term remission. LDSI can serve as an effective bridging therapy in refractory ATP associated with SLE, allowing safer splenectomy and sustained remission."

Journal • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • Thrombocytopenia • Thrombocytopenic Purpura

Drug repurposing for cytokine storm: baricitinib, ciclesonide, and acalabrutinib modulate cytokine release in a translational in vitro lymphoblastoid cell line model. (PubMed, Cytokine) - "We validated the model for cytokine-modulating drug screening using two well-established immunosuppressants, dexamethasone and cyclosporin A. Dexamethasone reduced IL-6 by 21 %, IL-8 by 71 %, IL-12 by 68 %, TNF-α by 83 %, and increased IL-10 by 51 %. Notably, LCL cells retained interindividual variability, as demonstrated by diverse cytokine as well as divergent NF-κB nuclear translocation responses, supporting the model's capacity to reveal real-world patient heterogeneity. Collectively, our findings establish LCL cells as a reproducible, immunologically responsive, and patient-representative platform for cytokine storm research and high-content drug testing, providing both mechanistic insight and translational relevance."

Journal • Preclinical • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • CXCL8 • IL10 • IL12A • IL6 • TNFA